Halley E. Gilbert net worth and biography

Halley Gilbert Biography and Net Worth

Director of Vaxcyte

Ms. Gilbert brings 20 years of operational, transactional, and strategic leadership experience within the biopharmaceutical sector to CytomX, having served in roles overseeing the transformation of companies from development to the commercial stage. Currently, Ms. Gilbert serves as the Chief Legal Officer of CARGO Therapeutics, a position she has held since September 2023. Ms. Gilbert has also previously served as the Chief Legal Officer at NeoGenomics Laboratories, where she oversaw NeoGenomics’ global legal functions and affairs. Additionally, Ms. Gilbert has served in numerous corporate leadership positions including chief operating officer at Adagio Therapeutics and senior vice president, corporate development and chief administrative officer, at Ironwood Pharmaceuticals. Prior to Adagio and Ironwood, Ms. Gilbert served as vice president, deputy general counsel at Cubist Pharmaceuticals, Inc., where she managed the legal function during the company’s first commercial launch of an acute care antibiotic. Prior to her time with Cubist, Ms. Gilbert served as corporate counsel at Genzyme Corporation. Ms. Gilbert began her career at the law firm of Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert currently serves on the board of Arcutis Biotherapeutics and Vaxcyte, Inc. Ms. Gilbert received a J.D. from Northwestern University School of Law and a B.A. from Tufts University.

What is Halley E. Gilbert's net worth?: The estimated net worth of Halley E. Gilbert is at least $627,637.50 as of June 3rd, 2024. Ms. Gilbert owns 5,625 shares of Vaxcyte stock worth more than $627,638 as of September 7th. This net worth estimate does not reflect any other assets that Ms. Gilbert may own. Learn More about Halley E. Gilbert's net worth.
How do I contact Halley E. Gilbert?: The corporate mailing address for Ms. Gilbert and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Halley E. Gilbert's contact information.
Has Halley E. Gilbert been buying or selling shares of Vaxcyte?: Halley E. Gilbert has not been actively trading shares of Vaxcyte during the last ninety days. Most recently, Halley E. Gilbert sold 18,200 shares of the business's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $73.00, for a transaction totalling $1,328,600.00. Following the completion of the sale, the director now directly owns 5,625 shares of the company's stock, valued at $410,625. Learn More on Halley E. Gilbert's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 49 times. They sold a total of 411,862 shares worth more than $27,439,668.67. The most recent insider tranaction occured on September, 3rd when COO Jim Wassil sold 10,000 shares worth more than $1,119,300.00. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 9/3/2024.

Halley E. Gilbert Insider Trading History at Vaxcyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/3/2024	Sell	18,200	$73.00	$1,328,600.00	5,625

Halley E. Gilbert Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $111.58

$110.48

$115.44

50 Day Range

MA: $81.80

$70.52

$112.10

2 Week Range

Now: $111.58

$44.20

$119.27

Volume

2,346,199 shs

Average Volume

833,799 shs

Market Capitalization

$12.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Tim Sykes’ Urgent Trade Alert: “Make this move now”

From Timothy Sykes | Ad

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade